Literature DB >> 23042445

Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer.

Jeanny B Aragon-Ching1.   

Abstract

Enzalutamide marks the latest addition to the drugs currently approved by the US Food and Drug Administration for metastatic, castration-resistant prostate cancer (mCRPC). AFFIRMwas a phase III international randomized trial that evaluated the clinical utility of enzalutamide versus placebo in men with mCRPC who have failed prior docetaxel-containing chemotherapy. Enzalutamide showed a remarkable 37% decreased risk of death with a median overall survival of 18.4 months versus 13.6 months for those who received placebo. These findings confirm the validity of further targeting the androgen receptor as a valid therapeutic approach in prostate cancer despite emergence of castration resistance.

Entities:  

Year:  2012        PMID： 23042445      PMCID： PMC3720116          DOI： 10.1038/aja.2012.113

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


  4 in total

1.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Authors:  Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers
Journal:  Lancet       Date:  2010-04-14       Impact factor: 79.321

2.  Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

Authors:  Charles J Ryan; Susan Halabi; San-San Ou; Nicholas J Vogelzang; Philip Kantoff; Eric J Small
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

3.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

4.  Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Authors:  Juliet Richards; Ai Chiin Lim; Colin W Hay; Angela E Taylor; Anna Wingate; Karolina Nowakowska; Carmel Pezaro; Suzanne Carreira; Jane Goodall; Wiebke Arlt; Iain J McEwan; Johann S de Bono; Gerhardt Attard
Journal:  Cancer Res       Date:  2012-03-12       Impact factor: 12.701
  4 in total
  3 in total

1.  High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.

Authors:  Kirsi Ketola; Miro Viitala; Pekka Kohonen; Vidal Fey; Zoran Culig; Olli Kallioniemi; Kristiina Iljin
Journal:  J Mol Biochem       Date:  2016-03-30

Review 2.  Metastatic castration-resistant prostate cancer: critical review of enzalutamide.

Authors:  Joelle El-Amm; Nihar Patel; Ashley Freeman; Jeanny B Aragon-Ching
Journal:  Clin Med Insights Oncol       Date:  2013-08-21

3.  Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.

Authors:  Sifeng Qu; Kendric Wang; Hui Xue; Yuwei Wang; Rebecca Wu; Chengfei Liu; Allen C Gao; Peter W Gout; Colin C Collins; Yuzhuo Wang
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.